Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

By C. Granger, J. McMurray, S. Yusuf, P. Held, E. Michelson, B. Olofsson, J. Ostergren, M. Pfeffer, K. Swedberg. The Lancet, 2003

1,671 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/569ebf85700d1ed65585fd33c90b0480ff26f05b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. G. Fonarow
2. T. Horwich
3. J. Januzzi
4. A. Takawale
5. Z. Kassiri
6. C. Yancy
7. M. Drazner
8. Véronique L. Roger

Citations in the corpus

• Extracellular Matrix Communication and Turnover in Cardiac Physiology and Pathology (2015, positive): “All major components of the renin-angiotensin-system (RAS) exhibit profibrotic activities, and angiotensin converting enzyme inhibitors (ACEi) (367), and angiotensin receptor blockers (ARBs) (127) have had beneficial effects in heart disease patients.”
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, neutral): “contraindicated, to reduce morbidity and mortality (108,345,415,450).”